Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis Inc. Class A (ZTS)
Last zoetis inc. class a earnings: 2/13 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.zoetis.com
Company Research
Source: Business Wire
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of science and research, with a safety profile demonstrated in a nine-month field study where dogs receiving Lenivia experienced increased mobility and decreased pain after one injection.“As pioneers in animal health innovation and veterinary monoclonal antibody development, our scientists at Zoetis are dedicated to thoroughly understanding the distinct biology of each species. This commitment fuels our discovery and development efforts to address our customers’ unmet medical needs,” said Rob Pol
Show less
Read more
Impact Snapshot
Event Time:
ZTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZTS alerts
High impacting Zoetis Inc. Class A news events
Weekly update
A roundup of the hottest topics
ZTS
News
- Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats [Yahoo! Finance]Yahoo! Finance
- Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in CatsBusiness Wire
- Zoetis Inc. (ZTS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Zoetis (NYSE:ZTS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $160.00 price target on the stock.MarketBeat
- Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript [Seeking Alpha]Seeking Alpha
ZTS
Earnings
- 11/4/25 - Beat
ZTS
Sec Filings
- 12/2/25 - Form 3
- 12/2/25 - Form 4
- 12/2/25 - Form 8-K
- ZTS's page on the SEC website